Royalty Pharma PLC (RPRX)
40.33
-0.73 (-1.78%)
USD |
NASDAQ |
Sep 23, 16:00
40.32
-0.01 (-0.02%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 17.70B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 10.58% |
| Valuation | |
| PE Ratio | 38.05 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 10.06 |
| Price to Book Value | 2.936 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.19 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 1.179 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
News
Headline
Wire
Time (ET)
Yahoo
09/09 09:15
SA Breaking News
08/15 17:00
Yahoo
08/13 08:05
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 11/10/2022* | -- | Results | Q3 2022 | -- | 0.72 | -- | |
| 11/10/2022* | 08:00 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/04/2022 | -- | Results | Q2 2022 | 0.79 | 0.78 | 1.36% | |
| 08/04/2022 | 08:00 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 05/05/2022 | -- | Results | Q1 2022 | 0.60 | 0.72 | -15.94% | |
| 05/05/2022 | 08:00 EST | Earnings Call | Q1 2022 | -- | -- | -- | |
| 02/15/2022 | -- | Results | Q4 2021 | 0.80 | 0.78 | 3.69% | |
| 02/15/2022 | 08:00 EST | Earnings Call | Q4 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. |
| URL | https://www.royaltypharma.com |
| Investor Relations URL | https://www.royaltypharma.com/investors |
| HQ State/Province | New York |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Nov. 10, 2022 (est.) |
| Last Earnings Release | Aug. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 18, 2022 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 0.72 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 1.346 |
| Yield to Sector | 1.036 |
| Yield to Industry | 2.665 |
| Last Dividend Amt. | 0.19 |
| Dividend Frequency | Quarterly |
| Last Ex-Dividend Date | Aug. 18, 2022 |
| Yield (TTM) | 1.83% |
| Forward Yield | 1.88% |
| Payout Ratio | 66.92% |
| Cash Payout Ratio | 15.64% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of September 23, 2022.
Fundamentals
| Revenue (TTM) | 2.259B |
| Total Expenses (TTM) | 1.205B |
| Net Income (TTM) | 466.10M |
| Total Assets (Quarterly) | 17.74B |
| Total Liabilities (Quarterly) | 7.332B |
| Shareholders Equity (Quarterly) | 6.027B |
| Cash from Operations (TTM) | 1.995B |
| Cash from Investing (TTM) | -1.416B |
| Cash from Financing (TTM) | 386.98M |
Ratings
Profile
Edit
| Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. |
| URL | https://www.royaltypharma.com |
| Investor Relations URL | https://www.royaltypharma.com/investors |
| HQ State/Province | New York |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Mid Cap/Blend |
| Next Earnings Release | Nov. 10, 2022 (est.) |
| Last Earnings Release | Aug. 04, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Aug. 18, 2022 |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| MGHRX | 411.48M USD | 6.68% |
| MBIRX | 125.10M USD | 6.28% |
| TAAEX | 112.13M USD | 6.11% |
| IHE | 17.79M USD | 4.45% |
| IPO | 5.744M USD | 3.63% |
| XPH | 7.184M USD | 3.38% |
| FACTX | 139.73M USD | 2.38% |
| FSPHX | 203.05M USD | 2.37% |
| QQQN | 1.941M USD | 2.04% |
| ZUH.TO | 6.739M USD | 1.60% |
| QQQJ | 11.75M USD | 1.59% |
| VHGEX | 89.09M USD | 1.27% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Morningstar | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| RPRX Tweets |